![](https://ml.globenewswire.com/media/c8e09eb2-c160-47a8-9edf-35291acd5ac3/small/bioasis-png.png)
Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology
NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the …